The 2026 European Neurofibromatosis conference will focus on patient involvement in Neurofibromatosis research and care, bringing together leading experts, clinicians, researchers, and patient representatives from across Europe and beyond. Together, we will explore the latest advances in understanding and managing Neurofibromatosis type 1, NF2-related and non-related Schwannomatosis, and discuss how collaborative approaches can improve both scientific progress and patient outcomes.
The 2026 European NF Conference will apply for CME accreditation through EACCME, the European accreditation body, which offers accreditation for events worldwide. EACCME credits are recognised by the AMA and RCPSC.
Preliminary Programme
Thursday, 12 November 2026
| Time | Sessions |
|---|---|
| 12:00-12:10 | Welcome |
| 12:10-12:40 | Keynote 1: From Neural Crest to Schwann Cell Lineage |
| 12:40-14:30 | Plenary 1: Genetic Aspects of Neurofibromatosis Type 1, Schwannomatosis and Related Disorders |
| 14:30-15:00 | Break / Posters |
| 15:00-16:30 |
Hall 1
Clinical Session 1: Neuropsychosocial Implications
Hall 2
Basic Session 1: Preclinical Models for Neurofibromatosis Type 1 and Schwannomatosis Pathogenesis |
| 16:30-16:45 | Break / Posters |
| 16:45-18:15 |
Hall 1
Clinical Session 2 (Joint with Basic Science): Bone and Orthopaedic Aspects of NF1
Hall 2
Basic Session 2: Basic Biology underlying Neurofibromatosis Type 1 and Schwannomatosis |
| 18:30-21:00 | Welcome Reception and Poster Session |
Friday, 13 November 2026
| Time | Sessions |
|---|---|
| 08:00-09:30 |
Hall 1
Clinical Session 3: Cutaneous Manifestations in Neurofibromatosis
Hall 2
Basic Session 3: Basic and Translational Research in Schwannomatosis: Selected from Abstracts |
| 09:30-09:50 | Break / Posters |
| 09:50-10:20 | Keynote 2: Evidence to Action - How Advocacy Works Best |
| 10:20-12:00 | Plenary 2: Together - Patient Involvement in Research and Clinic |
| 12:00-13:10 | Lunch Symposium during Lunch Break |
| 13:10-14:25 | Plenary 3: Malignant Progression from Neurofibroma to MPNST – Part 1 |
| 14:25-14:50 | Break / Posters |
| 14:50-16:10 | Plenary 3: Malignant Progression from Neurofibroma to MPNST – Part 2 |
| 16:10-16:30 | Break / Posters |
| 16:30-18:00 |
Hall 1
Clinical Session 4: SWN Basket Session (Pain, Hybrid Tumours, etc.)
Hall 2
Basic Session 4: Basic and Translational Research in Neurofibromatosis Type 1: Selected from Abstracts |
| 19:30-23:00 | Conference Dinner |
Saturday, 14 November 2026
| Time | Sessions |
|---|---|
| 08:00-08:45 | Keynote 3: Organoids |
| 08:45-10:10 | Plenary 4: CNS Tumours in Neurofibromatosis Type 1 and Schwannomatosis |
| 10:10-10:30 | Break / Posters |
| 10:30-11:50 |
Hall 1
Clinical Session 5: Imaging in Neurofibromatosis / SWN
Hall 2
Basic Session 5: Genomics and Bioinformatics for Neurofibromatosis Type 1 and Schwannomatosis |
| 11:50-13:00 | Lunch Symposium during Lunch Break |
| 13:00-14:00 |
Hall 1
Clinical Session 6: Rare Manifestations
Hall 2
Basic Session 6: AI and Big Data in Neurofibromatosis Type 1 and Schwannomatosis Research |
| 14:00-14:20 | Break / Posters |
| 14:20-14:40 | Poster Awards |
| 14:40-15:30 | Theodor Schwann Awards and Talk by Awardees |
| 15:30-16:30 | Plenary 5: New Therapeutic Developments – Future Clinical Trials and Clinical Trial Design – Preclinical Drug Development – Part 1 |
| 16:30-16:45 | Break / Posters |
| 16:45-17:45 | Plenary 5: New Therapeutic Developments – Future Clinical Trials and Clinical Trial Design – Preclinical Drug Development – Part 2 |
| 17:45-18:00 | Meeting Closure / Farewell |
Scientific Programme Committee
Clinical Science
- Assoc. Prof. Dr. Amedeo Azizi (AT)
- Dr. Laura Fertitta (FR)
Basic Science
- Ao. Prof. Dr. Katharina Wimmer (AT)
- Eduard Serra, PhD (ES)
Patient Advocate
- Ing. Claas Röhl (AT)
- Gilles Atlan (UK / IL)
Join the 2026 European Neurofibromatosis Conference in Vienna, 12–14 November. Explore advances in NF1, Schwannomatosis, and patient-centred research at Hyatt Regency Vienna (previously Andaz Vienna Am Belvedere).